| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| 100g |
|
||
| Other Sizes |
| Targets |
In biological systems, Anisoin has been shown to target phosphoinositide 3‑kinase alpha (PI3Kalpha), a critical enzyme in cancer cell signaling pathways. By inhibiting PI3Kalpha, anisoin can interfere with cell proliferation and survival pathways. It also exhibits antioxidant properties, which are crucial for combating oxidative stress in biological systems.
|
|---|---|
| ln Vitro |
In vitro, Anisoin exhibits significant antioxidant capabilities. It has been shown to inhibit PI3Kalpha, which is a key enzyme in the PI3K/Akt/mTOR signaling pathway. By inhibiting this pathway, the compound can reduce cancer cell proliferation and induce apoptosis. The antioxidant properties protect cells from oxidative damage, which is involved in various disease models, including inflammation, aging, and cancer.
|
| ln Vivo |
Anisoin is also a pre‑chromatographic fluorescent labeling reagent used for the analysis of guanidino compounds (Ex/Em = 325/435 nm). It is a biocompatible polymer used in a variety of medical applications. The material has been shown to have optical properties that can be exploited for chromatography and other types of chemical analysis, and it has the ability to bind to creatine.
|
| Enzyme Assay |
Non-cell-based experiments for anisoin primarily focus on its use as a fluorescent labeling reagent. A standard protocol for pre-column derivatization involves dissolving anisoin (e.g., 1 mg) in an organic solvent (e.g., methanol or acetonitrile) to a concentration of 0.1-1 mM. The guanidino-containing sample (e.g., creatinine, arginine, or guanidinoacetic acid) is dissolved in an aqueous buffer (e.g., 0.1 M borate buffer, pH 9.0). An equal volume of the anisoin solution is added to the sample and mixed. The mixture is heated (e.g., 60-80degC for 10-30 min) to allow the reaction to proceed. After cooling and filtration, the derivatized sample is injected into an HPLC system equipped with a fluorescence detector (Ex/Em = 325/435 nm). The chromatography uses a C18 reverse-phase column with a mobile phase of acetonitrile/water (gradient elution).
|
| Cell Assay |
Cell-based assays for anisoin are conducted to evaluate its anticancer and antioxidant properties. Human cancer cell lines (e.g., MCF-7 breast cancer, HeLa cervical cancer) are seeded in 96‑well plates and treated with varying concentrations of anisoin (1-100 uM) for 24-72 hours. Cell viability is measured by MTT assay. For antioxidant assays, cells can be treated with a pro‑oxidant (e.g., H2O2) in the presence or absence of anisoin, and intracellular reactive oxygen species (ROS) levels are measured using a fluorescent probe like DCFH-DA. The inhibition of PI3Kalpha can be confirmed by Western blotting for phospho-Akt (Thr308 and Ser473).
|
| Animal Protocol |
In vivo animal experiments for anisoin are not well documented. The compound is used primarily as an analytical reagent and for in vitro research. Based on its biocompatibility, it has been investigated for use as a filler for tissue engineering applications or as a coating on medical devices. For such applications, an implantable device coated with anisoin might be placed subcutaneously in a rat or mouse model to assess biocompatibility, inflammation, and tissue integration over a period of weeks to months.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for anisoin are limited. Based on its molecular weight (272.30) and lipophilicity (log P ~2.5), anisoin is moderately lipophilic. It is a solid at room temperature (melting point 110-112degC) and is soluble in organic solvents such as DMSO, ethanol, and methanol. It is stored at 2-8degC (refrigerated) in a sealed, dry container, protected from light. The fluorescence properties (Ex/Em = 325/435 nm) are useful for detection.
|
| Toxicity/Toxicokinetics |
The toxicity of anisoin is considered low. It is classified as a biocompatible polymer. As a research chemical, standard safety precautions apply: the compound may be harmful if swallowed, inhaled, or absorbed through the skin. It may cause skin and eye irritation. It should be handled in a well-ventilated area (fume hood) with appropriate PPE (lab coat, gloves, safety goggles). It is not for human use.
|
| References | |
| Additional Infomation |
Additional information: The compound has a molecular formula of C1₆H1₆O4 and a molecular weight of 272.30 g/mol. It is also known as 4,4'-Dimethoxybenzoin and 2-hydroxy-1,2-bis(4-methoxyphenyl)ethanone. The compound has a purity of 97% or higher from commercial suppliers and is for research and analytical use only.
|
| Molecular Formula |
C16H16O4
|
|---|---|
| Molecular Weight |
272.30
|
| Exact Mass |
272.105
|
| CAS # |
119-52-8
|
| PubChem CID |
95415
|
| Appearance |
Solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
20
|
| Complexity |
302
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC=C(C=C1)C(C(=O)C2=CC=C(C=C2)OC)O
|
| InChi Key |
LRRQSCPPOIUNGX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H16O4/c1-19-13-7-3-11(4-8-13)15(17)16(18)12-5-9-14(20-2)10-6-12/h3-10,15,17H,1-2H3
|
| Chemical Name |
2-hydroxy-1,2-bis(4-methoxyphenyl)ethanone
|
| Synonyms |
4,4'-Dimethoxybenzoin; 4,4′-DMB
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6724 mL | 18.3621 mL | 36.7242 mL | |
| 5 mM | 0.7345 mL | 3.6724 mL | 7.3448 mL | |
| 10 mM | 0.3672 mL | 1.8362 mL | 3.6724 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
